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Biochemical and molecular analysis
in mucopolysaccharidoses: what a
paediatrician must know
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Abstract
Mucopolysaccharidoses (MPS) are rare inherited disorders caused by a deficit of the lysosomal hydrolases involved
in the degradation of mucopolysaccharides, also known as glycosaminoglycans (GAGs). They are all monogenic
defects, transmitted in an autosomal recessive way, except for MPS type II which is X-linked. The enzymatic deficit
causes a pathologic accumulation of undegraded or partially degraded substrates inside lysosomes as well as in the
extracellular compartment. MPS generally present with recognizable signs and symptoms to raise a clinical
suspicion. However, although they have individual peculiarities, often signs and symptoms may overlap between
different MPS types. Therefore, a deeper evaluation of specific disease biomarkers becomes necessary to reach an
appropriate diagnosis. This paper stresses the central role of the laboratory in completing and confirming the
clinical suspicion of MPS according to a standardized procedure: first, a biochemical evaluation of the patient
samples, including qualitative/quantitative urinary GAG analysis and a determination of enzyme activities, and then
the molecular diagnosis. We also encourage a constant and close communication between clinicians and
laboratory personnel to address a correct and early MPS diagnosis.
Keywords: Laboratory tests, Mucopolysaccharides, Glycosaminoglycans, Molecular analysis, Pseudodeficiency,
Genetic counselling, Genotype-phenotype relationship, Lysosomal storage disorders
Background
The degradation of the glycosaminoglycans (GAGs or
mucopolysaccharides), a major component of the extra-
cellular matrix, joint fluid, and connective tissue, takes
place in the lysosomes. Under physiological conditions,
the main GAG chains — dermatan sulphate (DS), hepa-
ran sulphate (HS), keratan sulphate (KS), and chondro-
itin sulphate (CS) — are degraded by 11 lysosomal
hydrolases through the sequential removal of monosac-
charides followed by the removal of sulphate groups,
resulting in the complete degradation of the polysac-
charide to its individual components.
The deficit of any one of the 11 acid hydrolase activ-
ities gives rise to the progressive accumulation of GAGs
in most tissues and organ systems, as well as in urine.
Figure 1 illustrates the stepwise degradation of the main
GAG chains by specific enzymes, as well as the resulting
11 distinct types of mucopolysaccharidoses (MPS)
depending on the enzyme deficiency. Table 1 summa-
rises the various enzyme defects and the type(s) of accu-
mulated GAGs for each specific type/subtype of MPS.
The 11 genes involved in the different subgroups of
MPS have already been identified and characterized
(Table 2), as well as the hereditary transmission model:
all MPS have an autosomal recessive transmission with
the exception of MPS II, which exhibits an X-linked
pattern.
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Laboratory diagnosis
Biochemical assay
Preliminary diagnostic analyses range from semiquantita-
tive spot tests [1] to quantitative assays [2, 3] followed by
qualitative identification [4] of increased urinary GAGs.
It should be noted that none of these methods can be
considered diagnostic per se since false negative/positive
results are sometimes obtained. A relatively high incidence
of false negative urinary screening has been reported for
HS in MPS III patients with mild/intermediate clinical
phenotypes [5] (Filocamo, personal data). KS does not
form a reaction product with any of these routinely used
methods; hence, quantitative GAG assessment in Morquio
syndrome (MPS IV) is unreliable. An enzyme-linked im-
munosorbent assay (ELISA) technique has been shown to
quantify KS accurately in the urine and blood of patients
with Morquio syndrome type A [6]. It is also known that
several factors can interfere with the measurement of
urinary GAGs and lead to false positive results. For in-
stance, the presence of the anticoagulant heparin, and
blood or haemoglobin, as well as several diseases other
than MPS (leukaemia, rheumatic arthritis, diabetes, obes-
ity, etc.), may also lead to an abnormally high GAG excre-
tion in the urine [7, 8].
Moreover, assays using tandem mass spectrometry
(MS/MS) have been established to measure GAG levels
in serum or plasma and, more recently, on dried blood
spot (DBS). MS/MS, allowing for the simultaneous
measurement of several GAGs, provides a sensitive,
specific, and reproducible GAG analysis making it po-
tentially useful for the screening, prognosis, and moni-
toring of any therapeutic effect in MPS patients [9, 10].
Enzymatic assays
The first step in the diagnostic process includes specific
enzymatic assays in a variety of cells. Leukocytes,
Fig. 1 Stepwise degradation of the main glycosaminoglycan chains, heparan sulphate (HS), dermatan sulphate (DS), and keratan sulphate (KS).
The enzymes involved in the pathway are shown in black. Defective enzyme activity leading to the different types of mucopolysaccharidosis
(MPS) is indicated in blue. Note that the degradation pathway of chondroitin sulphates, being similar to that of DS, is not shown
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cultured lymphoblasts, or fibroblasts are generally used,
with the actual choice depending upon the characteristics
of the enzyme to be assessed as well as the corresponding
method of detection. Enzyme activities are generally
determined by fluorogenic (4-methylumbelliferyl) or,
rarely, chromogenic (p-nitrophenyl) substrates.
Dried blood spot (DBS) DBS testing is a good option
for new-born screening (NBS) for various lysosomal
storage disorders including some MPS [11–13].
Although this approach is helpful for certain disorders,
positive DBS results need to be validated by conven-
tional testing, in other words enzymatic assay in cellular
extracts and/or molecular analysis. It is important for
clinicians to understand how to interpret results from
DBS screening as in the near future it is likely that NBS
programmes will include DBS tests. For comprehensive
reviews on this topic the reader can consult a relevant
chapter in this same supplement.
Pseudodeficiency Generally, a deficient activity of one
of the 11 lysosomal enzymes involved in GAG degrad-
ation is associated with an MPS. However, there are in-
dividuals who show greatly reduced enzymatic activity
but remain clinically healthy. This condition, termed
enzymatic pseudodeficiency (Pd), is due to polymorphic
genetic variants and can affect some of these lysosomal
hydrolases. The potential presence of an enzymatic Pd
poses a limitation for enzymatic tests and should be in-
vestigated whenever the results from an enzymatic assay
do not concur with the clinical phenotype of the patient.
The currently known enzymatic pseudodeficiencies are
reported below, on a disease-by-disease basis.
Molecular analysis
Molecular testing, available for all MPS, follows the
enzymatic diagnosis and serves to refine the diagnosis; it
can also be extremely helpful in facilitating familial
genetic counselling. In fact, once the genotype of an in-
dividual affected patient has been ascertained, genetic
counselling should address the possible prediction of the
potential clinical phenotype, indications for the most
appropriate therapy, if any, and the prospect for identifi-
cation of any at-risk carriers in the family.
Figure 2 graphically represents the conventional
diagnostic flowchart.
Next-generation sequencing The use of massively
parallel sequencing analysis, known as next-generation
sequencing (NGS), is becoming increasingly common as
a fast and low-cost sequencing approach. It includes
whole-genome sequencing (WGS), whole-exome se-
quencing (WES), and the so-called “targeted resequen-
cing approach” with focused “gene panels” which are
designed to include genomic regions known to underlie
diseases grouped by clinical affinity. In the near future, it
is possible that gene analysis using NGS techniques will
replace preliminary tests based on enzyme activities or
metabolite concentrations. This would offer several advan-
tages, mainly in terms of speeding up the diagnosis in pa-
tients where a differential analysis is difficult to perform.
However, the NGS-based technology is not without
limitations. It should be taken into consideration that
Table 1 Classification and major characteristics of the mucopolysaccharidoses (MPS)
Type Syndrome OMIM # Enzyme defect Affected GAG
MPS IH Hurler 607014 α-L-iduronidase DS, HS
MPS IS Scheie 607,015
MPS IH/S Hurler-Scheie 607016
MPS II Hunter (severe) 309900 Iduronate 2-sulfatase DS, HS
Hunter (attenuated)
MPS IIIA Sanfilippo A 252900 Heparan N-sulfatase HS
MPS IIIB Sanfilippo B 252920 α-N-acetyl-D-glucosaminidase
MPS IIIC Sanfilippo C 252930 Acetyl CoA:α-glucosaminide-acetyltransferase
MPS IIID Sanfilippo D 252940 N-acetylglucosamine-6-sulfatase
MPS IVA Morquio A 253000 N-acetylgalactosamine-6-sulfatase KS, CS
MPS IVB Morquio B 253010 β-galactosidase KS
MPS VI Maroteaux-Lamy 253200 N-acetylgalactosamine-4-sulfphatase (arylsulphatase B) DS
MPS VII Sly 253220 β-glucuronidase DS, HS, CS
MPS IX – 601492 Hyaluronidase Hyluronan
MPS V and VIII are designations no longer used
CS chondroitin sulphate, DS dermatan sulphate, GAG glycosaminoglycan, HS heparan sulphate, KS Keratan sulphate
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this technology is “error-prone” and that the presence of
variants of unknown significance (VUS) can make data
analysis extremely complicated [14, 15]. Nor should we
overlook the ethical issue that could arise because of
potential incidental findings obtained from NGS-based
technology.
Finally, it should be stressed that, for orphan dis-
eases, it is often difficult to build a base of molecular
knowledge as mutations tend to be private and the
molecular classification of each novel variant neces-
sarily implies additional laboratory investigations such
as functional studies based on enzyme and metabolite
assays, which are both cumbersome and costly. With-
out such a validation, it is hard to decide whether a
new variant is disease-causing or benign and would
risk falling into the VUS category.
Genetic counselling All MPS are inherited as auto-
somal recessive disorders, except MPS II which is
X-linked and therefore only affects males except in
extremely rare cases. Once a definitive diagnosis is
achieved, genetic counselling can be offered to patients
and their families. Such counselling should explain the
mode of inheritance and the importance of testing
at-risk family members, it should yield an estimate of re-
currence risks, and provide information about prenatal
genetic tests and available therapeutic approaches.
Prenatal diagnosis is performed on the most appropri-
ate samples, which usually include fresh or cultured
chorionic villus samples obtained by villocentesis,
usually performed at approximately 12 weeks gestation,
or cultured amniotic fluid obtained via amniocentesis at
approximately 16 weeks gestation. The choice of the
test, enzymatic and/or molecular, is based on the charac-
teristics of the defect to be investigated. Prenatal mo-
lecular testing requires the genotype of the family index
case to be known. The availability of both tests (enzym-
atic and molecular) enormously increases the reliability
of the diagnosis. Hence, biochemical and molecular gen-
etic testing are usually complementary for the prenatal
diagnosis of MPS. However, special considerations are
required for the prenatal diagnosis of Hunter syndrome,
the only X-linked MPS. Since in a female carrier a
skewed distribution of the cells expressing the mutant
allele might yield results resembling those of an affected
male fetus, the usual procedure is to determine fetal sex
and only if the karyotype is 46,XY would fetal cells be
biochemically analysed antenatally.
Fig. 2 Diagnostic flow chart for mucopolysaccharidoses (MPS). The diagnosis of the MPS can be performed starting with a screening of the urine
followed by quantitative assay of urinary glycosaminoglycans (GAGs) and, if available, by qualitative evaluation of the GAGs accumulated that can
steer the enzymatic assay. Once the enzymatic defect has been determined, the molecular analysis will serve to identify the causative genomic
variant. Note that keratan sulphate (KS) does not form a reaction product with any of the routinely methods reported here; hence, quantitative
GAG assessment in Morquio syndrome (MPS IV) requires other techniques or the two enzymatic assays. Differential laboratory diagnosis includes
multiple sulphatase deficiency and mucolipidosis II and III, in which GAGs accumulate because of their primitive defect involving some of the
enzymes of the GAG degradation pathway. HS heparan sulphate, DS dermatan sulphate
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Biobanking Since our understanding of genes, muta-
tions, and diseases is continually improving, consider-
ation should be given to biobanking samples and data
from affected individuals, as well as from their parents
and first-degree relatives, for future diagnostic and
research purposes [16].
More comprehensive information on diagnosis and
management of individual MPS is provided in some
recently published guidelines [17–22].
Molecular genetics: Trying to understand the genotype-
phenotype relationship
The elucidation of the molecular mechanisms under-
lying the MPS began in the 1990s. The process of clon-
ing the diverse genes encoding the lysosomal enzymes
involved in the GAG degradative pathways lasted until
2006 with the identification of the gene responsible for
MPS IIIC. Although the large variety of mutations
responsible for any MPS has often hampered the estab-
lishment of clear genotype–phenotype correlations,
some general conclusions can be drawn in relation to re-
current mutations and are usually based on prior
observations in large series of patients. However, even in
the presence of a recurrent mutation, some patients
carrying the same molecular lesion may present with
different clinical phenotypes, suggesting that other
variants at other gene loci and/or some environmental
factors can modulate the clinical phenotype. This may
be particularly important in the case of parents’ consan-
guinity, which is quite common in some ethnic groups
due to geographical reasons or to the practice of
arranged marriages [23–25].
Table 2 summarises the characteristics and types of
mutations of the 11 genes responsible for the different
MPS, as reported in the Human Gene Mutation
Database [26].
MPS I
The gene encoding α-L-iduronidase (IDUA; MIM
#252800) maps to chromosome 4p16.3 and contains 14
exons encoding for a polypeptide of 653 amino acids
[27]. A deficiency of this enzyme results in the lack of
degradation of DS and HS and their progressive
accumulation. To date, at least 257 IDUA mutations are
known, spread along the entire coding and splicing re-
gions (Table 2). MPS I is a highly heterogeneous dis-
order with a wide spectrum of clinical manifestations
[28, 29]. Overall, most mutations are ‘private’ with very
few pan-ethnic mutations, the two most common being
the p.Trp402X and p.Gln70X mutations found to be as-
sociated with a severe phenotype, and the p.Pro533Arg
associated with an intermediate-severe phenotype; the
p.Gly51Asp and p.Pro496Arg mutations have been
found until now only in Italian patients, associated with
a severe phenotype [30].
MPS I diagnosis can be hampered by the occurrence
of α-L-iduronidase Pd. Although only the variant
p.Ala300Thr has been reported so far as being associated
with enzymatic Pd [31], other variants (p.Ala79Thr,
p.His82Gln, p.Asp223Asn, and p.Val322Glu) are under
investigation as candidates for Pd [32, 33]. Therefore, as
NBS for MPS I has begun in some countries, it is
imperative to follow-up a real deficient α-L-iduronidase
result with urinary GAG analysis and IDUA gene se-
quencing prior to initiating treatment for MPS I.
MPS II
The iduronate 2-sulfatase gene (IDS; MIM #300823)
contains nine exons and spans ~ 24 kb on Xq28. The
1650 bp open reading frame of the IDS gene is predicted
to encode a 550-amino acid polypeptide [34]. The en-
zyme cleaves the sulphate group in position 2 of HS and
DS; thus, its deficit results in the diffused pathological
deposit of the both GAGs in most body districts. No
cases with significant residual enzymatic activity have so
far been described. A pseudogene, IDS2, presenting
more than 88% homology with IDS exons 2 and 3, as
well as introns 2, 3, and 7, is located 20 kb telomeric to
the functional gene but in the opposite orientation [34].
The presence of the pseudogene renders molecular diag-
nosis more difficult to perform, since appropriate
primers need to be designed to selectively avoid amplifi-
cation of the homologous pseudogene sequences. To
date, 628 different mutations in the IDS gene have been
reported (Table 2). Among these, gross alterations
including insertions, deletions, and gene-pseudogene
recombinational rearrangements represent about 12%
(76/628) of all known IDS gene lesions, 29% are small
deletions, insertions and indels and 9% (59/628) are spli-
cing mutations, while about 50% (313/628) are mis-
sense/nonsense variants. The de novo occurrence of IDS
gene mutations has sometimes been demonstrated by
family studies in large MPS II cohorts. Whilst germline
mosaicism has been assumed in some cases, this has
only rarely been formally demonstrated [35]. No
high-frequency recurring mutations have been reported
which has tended to constrain studies of the
genotype-phenotype relationship. However, an approxi-
mate relationship may be based on the observation that,
while missense variations may be associated with both
severe and attenuated phenotypes, nonsense variants,
splicing transcriptional defects, gross rearrangements, or
deletions/insertions are more commonly associated with
severe phenotypes. A recent study conducted on 65
Japanese families showed that missense variants were
mainly associated with attenuated phenotypes (87.5%)
and less frequently with severe phenotypes (29.3%) [36].
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Additionally, identical mutations have been found in pa-
tients with both mild and severe disease, implying the
possible contribution of other genetic or environmental
modifiers on the phenotype [35, 37, 38]. Rare female
MPS II patients have also been reported, mostly due to
the non-random inactivation of the X chromosome
(XCI) [27, 39–42]. Very rarely, a female MPS II patient
may be due to a balanced reciprocal translocation in-
volving one X chromosome, coupled with a skewed XCI
of the normal X chromosome [43].
MPS IIIA
The HS sulphatase gene (SGSH; MIM #605270)
spanning about 11 kb in length, comprises 8 exons. The
most prominent of the three demonstrated transcripts
(3.1, 4.3, and 7.1 kb) in most tissues, that of 3.1 kb,
encodes a 502-amino acid sulphamidase protein [44].
The deficit of the heparan N-sulphatase enzyme results
in the accumulation of the HS in organs and tissues. To
date, of the 145 mutations reported in Table 2, only
general conclusions have been drawn for p.Arg245His,
p.Gln380Arg, p.Ser66Trp, and p.Val361SerfsX52 muta-
tions, which have been found to be related to the devel-
opment of a severe phenotype, while p.Gly122Arg,
p.Arg206Pro, p.Ser298Pro, p.Ile322Ser, and p.Glu369Lys
mutations have been reported as being associated with
an attenuated phenotype [45]. Overall, no pan-ethnic
recurrent mutations have been reported, although some
mutations predominate in different ethnogeographic
groups, reflecting possible founder effects. In particu-
lar, p.Arg74Cys and p.Val361SerfsX52 are frequent in
Poland (56%) and Spain (45%), p.Arg245His in
Germany (35%) and Holland (57%), and p.Ser66Trp in
Italy (29%) [46–48].
MPS IIIB
The gene encoding α-N-acetyl-D-glucosaminidase
(NAGLU; MIM #609701) is approximately 8.5 kb in
length and comprises 6 exons. Its transcript of 2.7 kb
encodes a protein of 743 amino acids [49, 50]. The de-
fect of α-N-acetyl-D-glucosaminidase enzyme causes the
accumulation of the HS in organs and tissues. A total of
166 NAGLU mutations have been described (Table 2).
All the reported mutations occur at low frequencies, in-
dicating an extensive NAGLU mutational heterogeneity
which is likely to be responsible for the wide clinical
spectrum of MPS IIIB. Some predictions have been
made for p.Phe48Lys, p.Gly69Ser, p.Ser612Gly, and
p.Arg643Cys mutations that appear to be related to a
less severe clinical phenotype [51]. However, common
mutations have not been identified in MPS IIIB patients.
A potential complication reported in MPS IIIB is the sim-
ultaneous presence of the two polymorphisms p.Ser141Ser
and p.Arg737Gly producing a pseudodeficiency allele that
leads to a reduced level of α-N-acetyl-D-glucosaminidase
activity (Filocamo, personal data).
MPS IIIC
The heparin acetyl CoA:α-glucosaminide-N-acetyltrans-
ferase gene (HGSNAT; MIM #610453) contains 18 exons
generating a 1908-base pair cDNA that encodes a
635-amino acid protein. The deficit of acetyl CoA:α-glu-
cosaminide-acetyltransferase leads to the accumulation
of HS in organs and tissues. To date, 68 mutations have
been described for the HGSNAT gene (Table 2). Only
two mutations (p.Arg344Cys and p.Ser518Phe) have
been reported with a higher frequency in the Dutch
population [52]. Despite the identification of several
MPS IIIC-causing mutations, it has proven difficult to
establish a clear genotype-phenotype correlation, except
in a few cases such as mutations p.Gly262Arg and
p.Ser539Cys from two patients that were associated with
an attenuated phenotype [53, 54].
MPS IIID
The α-N-acetylglucosamine-6-sulphate sulphatase gene
(GNS; MIM #607664) consists of 14 exons spanning
approximately 46 kb of DNA; the predicted protein has
552 amino acids [55, 56]. The defect of N-acetylglucosa-
mine-6-sulphatase causes the accumulation of HS in or-
gans and tissues. Only 25, mostly private, disease-causing
mutations in MPS IIID patients have been reported to
date, thereby hampering genotype-phenotype correlation
studies (Table 2).
MPS IVA
In MPS IVA, or Morquio A, the deficient activity of
N-acetylgalactosamine-6-sulphatase (GALNS) causes ac-
cumulation of the GAGs KS and CS in multiple tissues
with skeletal and connective tissue abnormalities [57].
The GALNS gene, encoding the lysosomal enzyme
N-acetylgalactosamine-6-sulphatase (GALNS; E.C.
3.1.6.4; MIM #612222), maps to chromosome 16q24.3,
has a length of about 50 kb, and is organized into 14
exons [58]. The GALNS cDNA is 2339 bp in length with
a 1566-bp open reading frame encoding a 522-amino
acid protein [58, 59]. The GALNS protein is found as a
homodimer, but it has also been described in a multipro-
tein complex with other lysosomal enzymes [60].
To date, at least 333 different GALNS gene muta-
tions causing Morquio A disease have been described
(see the Human Gene Mutation Database [26]). Most
of them are ‘private’, with only a few being common.
Genotype-phenotype correlations have been reported
for some of the recurrent mutations, representing
founder alleles in certain population groups [61].
Thus, the p.Ile113Phe [62] and p.Thr312Ser missense
variants recur in patients of British-Irish origin and a
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milder phenotype has been associated with the re-
sidual activity of the mutant p.Thr312Ser protein [63].
In the GALNS gene, large deletions and/or rearrange-
ments and a uniparental disomy have also been reported
[64–66]. Deep intronic mutations have also been de-
tected (Morrone, personal data). So far, no pseudodefi-
ciency has been described in the GALNS gene.
MPS IVB
The β-galactosidase gene (GLB1; E.C.3.2.1.23; MIM
#611458) maps to chromosome 3p22.3, spans more than
60 kb, and is organized into 16 exons [67]. The GLB1
gene gives rise to two alternately spliced mRNAs: a
transcript of 2.5 kb encoding the lysosomal enzyme
β-galactosidase and a transcript of 2.0 kb encoding
the elastin-binding protein (EBP). Both GLB1 tran-
scripts form protein complexes. β-galactosidase lyso-
somal enzyme or GLB1 is stabilised in a lysosomal
multienzyme complex with protective protein/cathep-
sin A (PPCA), neuraminidase (NEU1), and N-acetyl
galactosamine-6-sulphatase (GALNS) [60]. EBP is re-
quired for the assembly of tropoelastin monomers
into elastic fibres on the cell surface where it forms a
complex with PPCA and NEU1 [60, 68, 69].
Mutations in the GLB1 gene are responsible for two
allelic disorders: the neurodegenerative GM1 gangliosi-
dosis (non-MPS) disorder (MIM 230500) and the rare
MPS IVB (Morquio B) syndrome (MIM 253010) [70]. In
contrast to GM1 gangliosidosis, patients with Morquio
B retain neurological functions, but develop generalized
skeletal dysplasia, keratan sulphaturia, and corneal
clouding [71]. However, the clinical demarcation be-
tween GM1 and Morquio B at an early stage of diagnosis
can be very difficult and obscured by a late-onset mental
regression and by the presence of keratan sulphaturia in
juvenile GM1 gangliosidosis forms.
The GLB1 mutations underlying Morquio B syndrome
affect the catabolism of KS but have little effect on GM1
gangliosides.
To date, 215 GLB1 gene mutations have been re-
ported (see the Human Gene Mutation Database
[26]); among these, 22 were also identified in patients
with Morquio B but only a few can be related to the
specific phenotype [72–74]. The c.817_818del TG
insCT leading to p.Trp273Leu is one of the most
common mutations leading to a Morquio B pheno-
type [72].
Some GLB1 mutations have been identified in both
GM1 and Morquio B, and the same genetic assessment
has been shown in patients who exhibited different
symptoms, further complicating possible prognoses in
these individuals [72–74]. The common p.Arg201His de-
tected at the heterozygous level has been correlated with
the juvenile GM phenotype but it has also been detected
in a 15-year-old Morquio B patient harbouring the mu-
tation at the homozygous level [73]. Thus, phenotypes in
compound GLB1 heterozygous genotypes sometimes re-
main difficult to predict [75, 76]. In addition, the GLB1
gene polymorphic variants p.Arg521Cys, p.Ser532Gly,
and p.Arg595Trp have been reported to be associated
with beta-galactosidase enzymatic pseudodeficiency [77].
MPS VI
The N-acetylgalactosamine 4-sulphatase (arylsulphatase
B) gene (ARSB; MIM #611542), located in 5q14.1, spans
a region of about 206 kb and contains 8 exons encoding
a 533-amino acid glycoprotein [78]. ARSB deficit causes
a pathological accumulation of undegraded DS in most
organ systems. Presently, 197 different alterations have
been reported, the vast majority of which are missense/
nonsense lesions (Table 2). Since no common mutations
have been reported up to now, the potential for studies
of genotype-phenotype correlation in MPS VI is some-
what limited. Only one pseudodeficiency allele was re-
ported a few years ago, p.Thr212Ile, in a family for
which very low ARSB enzyme activity was described in
relation to normal clinical findings [79]. Interestingly,
the p.Ser384Asn (S384 N), one of the most common
polymorphisms of the gene [80], had been traded for
several years as a pathogenetic variant and correlated
with a severe phenotype, leading to a series of incorrect
molecular diagnoses of the ARSB gene [81].
MPS VII
The gene encoding β-glucuronidase (GUSB; MIM
#611499) is 21 kb long and contains 12 exons. Two
types of cDNAs arise through alternative splicing, result-
ing in an exon 6 corresponding to the 153-bp deletion in
the shorter of the two types [82]. The presence of un-
processed multiple pseudogenes requires particular at-
tention in diagnostic mutation analysis. To date, 64
different mutations have been reported in the GUSB
gene (Table 2). Another complication reported in MPS
VII diagnosis is the presence of the missense poly-
morphism p.Asp152Asn producing a pseudodeficiency
allele that leads to greatly reduced levels of
beta-glucuronidase activity (27% of the control) without
apparent deleterious consequences [83].
MPS IX
The gene encoding hyaluronidase (HYAL1; MIM
#607071) contains 3 exons and spans 3.5 kb [84].
HYAL1, together with HYAL2 and HYAL3, constitutes a
multigene family for lysosomal hyaluronidase. To date,
only one patient in the original report, and three others
belonging to a second family have been described, yield-
ing a total of three different mutations responsible for
the disease (Table 2) [85, 86].
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Conclusions
Although MPS share many clinical features among dif-
ferent enzyme deficiencies, they can also show a wide
spectrum of clinical severity within each enzyme defi-
ciency. Hence, even in the presence of typical clinical
signs and symptoms, the choice of samples and diagnos-
tic tests can be different for each MPS and require a
multidisciplinary approach, including laboratory special-
ists and clinicians.
Increased urinary excretion of GAGs may only support
the clinical suspicion of MPS and it is necessary to fol-
low this with specific genetic testing including enzymatic
and/or molecular analyses, performed on suitable sam-
ples, as leukocytes and/or cultured cell lines. While both
analyses must be considered complementary for the de-
finitive diagnosis of MPS and the genetic counselling,
the molecular analysis is essential for carrier detection,
and can sometimes predict prognosis and support thera-
peutic choices. The recently proposed NGS techniques
will very soon complement the conventional testing, in
particular for those patients where a differential diagno-
sis is difficult to perform.
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